Although there were only 26 patients with luminal B-type breast cancer who received NAC in this study, it is clear that the prognosis of HER2 + and HER2− luminal B-type breast cancer is significantly different under standard of care. The gene discussed is ERBB2; the disease is breast carcinoma.